JP2021006549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021006549A5 JP2021006549A5 JP2020164335A JP2020164335A JP2021006549A5 JP 2021006549 A5 JP2021006549 A5 JP 2021006549A5 JP 2020164335 A JP2020164335 A JP 2020164335A JP 2020164335 A JP2020164335 A JP 2020164335A JP 2021006549 A5 JP2021006549 A5 JP 2021006549A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- complex compound
- acceptable salt
- compound according
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 51
- 150000003839 salts Chemical class 0.000 claims 49
- 230000008614 cellular interaction Effects 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 230000012202 endocytosis Effects 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 8
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 7
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- -1 small molecule compounds Chemical class 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 102000000853 LDL receptors Human genes 0.000 claims 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940014144 folate Drugs 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 150000002224 folic acids Chemical class 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims 2
- 235000007635 levomefolic acid Nutrition 0.000 claims 2
- 239000011578 levomefolic acid Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- VVEJUSYNERNRME-XGFVQVCISA-N (4r,7s,10r,13s,16r,19s,22r,25s,28r,31s)-13,28-bis(4-aminobutyl)-25-(2-amino-2-oxoethyl)-31-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-19,22-dibenzyl-10-[(1r)-1-hydroxyethyl]-7-(hydroxymethyl)-16-(1h-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo- Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 VVEJUSYNERNRME-XGFVQVCISA-N 0.000 claims 1
- FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical group CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 claims 1
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 claims 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 101500024338 Homo sapiens Somatostatin-14 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000008238 LHRH Receptors Human genes 0.000 claims 1
- 108010021290 LHRH Receptors Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 claims 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102400000820 Somatostatin-14 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000003569 TRPV6 Human genes 0.000 claims 1
- 101150096736 TRPV6 gene Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- VLXBWPOEOIIREY-UHFFFAOYSA-N dimethyl diselenide Natural products C[Se][Se]C VLXBWPOEOIIREY-UHFFFAOYSA-N 0.000 claims 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical group CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 claims 1
- 108010004914 prolylarginine Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192575A JP2023025151A (ja) | 2015-08-11 | 2022-12-01 | 多リガンド－薬物複合体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510489556.6A CN106466485B (zh) | 2015-08-11 | 2015-08-11 | 一种具有细胞内吞介导功能的靶向配体-药物偶联体 |
| CN201510489560.2 | 2015-08-11 | ||
| CN201510489556.6 | 2015-08-11 | ||
| CN201510489560.2A CN106466484B (zh) | 2015-08-11 | 2015-08-11 | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 |
| JP2017568345A JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568345A Division JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192575A Division JP2023025151A (ja) | 2015-08-11 | 2022-12-01 | 多リガンド－薬物複合体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021006549A JP2021006549A (ja) | 2021-01-21 |
| JP2021006549A5 true JP2021006549A5 (enExample) | 2021-03-04 |
| JP7573401B2 JP7573401B2 (ja) | 2024-10-25 |
Family
ID=57983917
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568345A Active JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
| JP2020164335A Active JP7573401B2 (ja) | 2015-08-11 | 2020-09-30 | 多リガンド－薬物複合体及びその使用 |
| JP2022192575A Pending JP2023025151A (ja) | 2015-08-11 | 2022-12-01 | 多リガンド－薬物複合体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568345A Active JP6772199B2 (ja) | 2015-08-11 | 2016-08-11 | 多リガンド−薬物複合体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192575A Pending JP2023025151A (ja) | 2015-08-11 | 2022-12-01 | 多リガンド－薬物複合体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11571480B2 (enExample) |
| EP (1) | EP3334500B1 (enExample) |
| JP (3) | JP6772199B2 (enExample) |
| KR (2) | KR102464778B1 (enExample) |
| CN (3) | CN108135881B (enExample) |
| AU (2) | AU2016305703B2 (enExample) |
| CA (1) | CA2987322C (enExample) |
| DK (1) | DK3334500T3 (enExample) |
| ES (1) | ES2877409T3 (enExample) |
| MX (1) | MX381031B (enExample) |
| RU (1) | RU2722449C2 (enExample) |
| WO (1) | WO2017025057A1 (enExample) |
| ZA (1) | ZA201707464B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2445932B1 (en) | 2009-06-26 | 2018-02-28 | Soricimed Biopharma Inc. | Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery |
| CN108135881B (zh) * | 2015-08-11 | 2020-11-13 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| EP3716991A4 (en) * | 2017-12-01 | 2021-09-08 | Soricimed Biopharma Inc. | TRPV6 INHIBITORS AND POLYTHERAPIES FOR THE TREATMENT OF CANCERS |
| WO2019109188A1 (en) * | 2017-12-06 | 2019-06-13 | Ontario Institute For Cancer Research (Oicr) | Acyl hydrazone linkers, methods and uses thereof |
| CA3086366A1 (en) | 2017-12-22 | 2019-06-27 | Ontario Institute For Cancer Research (Oicr) | Heterocyclic acyl hydrazone linkers, methods and uses thereof |
| WO2019134018A1 (en) * | 2018-01-05 | 2019-07-11 | Telethon Kids Institute | Vaccine conjugates and uses thereof |
| BR112021015109A2 (pt) * | 2019-01-30 | 2022-01-11 | Coherent Biopharma Suzhou Ltd | Conjugado de fármaco-ligante duplo e uso do mesmo |
| JP2022542560A (ja) * | 2019-07-22 | 2022-10-05 | パーデュー・リサーチ・ファウンデーション | 線維芽細胞を標的とする多価作用物質、および使用方法 |
| CA3151858A1 (en) * | 2019-08-20 | 2021-02-25 | Egi Tech (Shen Zhen) Co., Limited | Method for sequencing polynucleotides based on optical signal kynetics of luminescent labels and secondary luminescent signals |
| WO2021163701A1 (en) * | 2020-02-13 | 2021-08-19 | Escape Therapeutics, Inc. | Melanoma therapeutics |
| EP4274595A1 (en) * | 2021-01-07 | 2023-11-15 | Purdue Research Foundation | Folate receptor-targeted conjugates, compositions, and delivery to the central nervous system |
| CA3224741A1 (en) * | 2021-06-25 | 2022-12-29 | Coherent Biopharma (Suzhou), Limited | Ligand-drug conjugate and use thereof |
| CN116059392B (zh) * | 2021-09-03 | 2025-02-28 | 同宜医药（苏州）有限公司 | 配体偶联物及其应用 |
| WO2023036193A1 (zh) * | 2021-09-08 | 2023-03-16 | 同宜医药（苏州）有限公司 | 药物制剂及其制备方法和用途 |
| AU2022371507A1 (en) * | 2021-10-19 | 2024-05-02 | Coherent Biopharma (Suzhou) Limited | Conjugate drug preparation, preparation method therefor and use thereof |
| CN116196408A (zh) * | 2021-12-30 | 2023-06-02 | 思格(苏州)生物科技有限公司 | 一种新型免疫佐剂及其制备方法和应用 |
| TW202404643A (zh) * | 2022-04-20 | 2024-02-01 | 大陸商同宜醫藥（蘇州）有限公司 | 化合物及用途 |
| TW202421200A (zh) * | 2022-11-09 | 2024-06-01 | 大陸商同宜醫藥（蘇州）有限公司 | 透過施用配體－藥物偶聯體治療癌症 |
| CN120813385A (zh) * | 2023-03-23 | 2025-10-17 | 同宜医药（苏州）有限公司 | 通过施用配体-药物偶联体治疗卵巢癌 |
| CN121001746A (zh) * | 2023-04-26 | 2025-11-21 | 同宜医药（苏州）有限公司 | 一种配体-药物偶联体在治疗癌症中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| US20030129188A1 (en) | 2001-10-22 | 2003-07-10 | The Scripps Research Institute | Integrin targeting compounds |
| EP1531846A4 (en) * | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| GB0209893D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7119168B2 (en) * | 2002-11-18 | 2006-10-10 | Bioprospecting Nb Inc. | Paralytic peptide for use in neuromuscular therapy |
| US7935677B2 (en) | 2003-12-05 | 2011-05-03 | Cedars-Sinai Medical Center | Polymalic acid-based multi-functional drug delivery system |
| US20100166654A1 (en) | 2004-12-03 | 2010-07-01 | The Uab Research Foundation | Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery |
| BRPI0615354A2 (pt) | 2005-08-19 | 2011-05-17 | Endocyte Inc | conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso |
| JP5290756B2 (ja) | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
| CN101541332A (zh) * | 2006-09-15 | 2009-09-23 | 安佐制药股份有限公司 | 含多官能连接基的靶向聚合物前药 |
| US20080181852A1 (en) | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
| CN101224306B (zh) | 2008-02-20 | 2011-04-20 | 中山大学 | 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法 |
| JP2012509066A (ja) * | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための放出可能接合体 |
| CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2012019121A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Trustees Of The University Of Illinois | Multiplexed supramolecular assemblies for non-viral delivery of genetic material |
| IN2014DN00101A (enExample) | 2011-06-06 | 2015-05-15 | Starpharma Pty Ltd | |
| CN107496932A (zh) * | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CN103372199B (zh) * | 2012-04-16 | 2015-12-16 | 广州暨南大学医药生物技术研究开发中心 | 一种预防和治疗神经退行性疾病的新型脑部靶向制剂 |
| WO2013170272A2 (en) * | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| GB201211309D0 (en) | 2012-06-26 | 2012-08-08 | Fujifilm Mfg Europe Bv | Process for preparing membranes |
| EP2869847B1 (en) | 2012-07-09 | 2017-12-06 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
| PL3210627T3 (pl) * | 2012-07-12 | 2023-04-17 | Hangzhou Dac Biotech Co., Ltd | Koniugaty zawierające cząsteczki wiążące się z komórką i środek cytotoksyczny |
| CA2890455A1 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| US10253099B2 (en) | 2012-12-05 | 2019-04-09 | Ruprecht-Karls-Universität Heidelberg | Conjugates of proteins and multivalent cell-penetrating peptides and their uses |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| WO2015057876A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| CN104784699B (zh) * | 2014-01-20 | 2019-05-03 | 博瑞生物医药（苏州）股份有限公司 | 叶酸受体结合配体-药物偶联物 |
| EP3164420A4 (en) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| CN104667292B (zh) * | 2015-02-02 | 2017-09-05 | 北京大学 | 一种还原响应型药物偶联物纳米粒的制备及其应用 |
| MA48709A (fr) * | 2015-05-12 | 2020-04-08 | Blinkbio Inc | Conjugués de médicament à base de silicium et leurs procédés d'utilisation |
| CN108135881B (zh) * | 2015-08-11 | 2020-11-13 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| JP2020164335A (ja) * | 2019-03-28 | 2020-10-08 | イビデン株式会社 | ハニカム構造体 |
-
2016
- 2016-08-11 CN CN201680045855.3A patent/CN108135881B/zh active Active
- 2016-08-11 EP EP16834681.5A patent/EP3334500B1/en active Active
- 2016-08-11 CN CN202011155574.8A patent/CN112263683A/zh active Pending
- 2016-08-11 KR KR1020207016784A patent/KR102464778B1/ko active Active
- 2016-08-11 ES ES16834681T patent/ES2877409T3/es active Active
- 2016-08-11 AU AU2016305703A patent/AU2016305703B2/en active Active
- 2016-08-11 RU RU2018104266A patent/RU2722449C2/ru active
- 2016-08-11 DK DK16834681.5T patent/DK3334500T3/da active
- 2016-08-11 JP JP2017568345A patent/JP6772199B2/ja active Active
- 2016-08-11 WO PCT/CN2016/094704 patent/WO2017025057A1/en not_active Ceased
- 2016-08-11 CA CA2987322A patent/CA2987322C/en active Active
- 2016-08-11 US US15/751,541 patent/US11571480B2/en active Active
- 2016-08-11 KR KR1020187003716A patent/KR102301596B1/ko active Active
- 2016-08-11 MX MX2018001723A patent/MX381031B/es unknown
- 2016-08-11 CN CN202010115950.4A patent/CN111617250B/zh active Active
-
2017
- 2017-11-03 ZA ZA2017/07464A patent/ZA201707464B/en unknown
-
2019
- 2019-10-02 AU AU2019240611A patent/AU2019240611B2/en active Active
-
2020
- 2020-09-30 JP JP2020164335A patent/JP7573401B2/ja active Active
-
2022
- 2022-10-06 US US17/961,397 patent/US20240100175A1/en active Pending
- 2022-12-01 JP JP2022192575A patent/JP2023025151A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021006549A5 (enExample) | ||
| JP2023025151A5 (enExample) | ||
| RU2018104266A (ru) | Полилигандные лекарственные конъюгаты и их применения | |
| JP7546574B2 (ja) | 二重リガンド薬物コンジュゲート及びその使用 | |
| Wang et al. | Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells | |
| Ellert-Miklaszewska et al. | Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment | |
| CN108473541A (zh) | 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物 | |
| CN104271590A (zh) | 用于癌治疗的肽剂 | |
| ES2908470T3 (es) | Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos | |
| KR20160064726A (ko) | 세포 투과 펩타이드-항암제 접합체 및 이를 포함하는 암 치료용 조성물 | |
| AU2013334334B2 (en) | rTRAIL mutant and monomethyl auristatin E conjugate thereof | |
| US20230173083A1 (en) | Albumin-binding prodrug for preventing or treating cancer and pharmaceutical composition including the same | |
| JP2022539270A (ja) | Ｃｄ３８結合剤およびその使用 | |
| CA3127903A1 (en) | Bi-ligand drug conjugate and use thereof | |
| Yukimatsu Toh et al. | Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer. | |
| RU2820346C2 (ru) | Билигандный конъюгат лекарственного средства и его применение | |
| HK40052006A (en) | Bi-ligand drug conjugate and use thereof | |
| Ding et al. | Engineering Bispecific Peptides for Precision Immunotherapy and Beyond | |
| HK40061762A (en) | Bi-ligand drug conjugate and use thereof | |
| HK1250634B (zh) | 多配体药物偶联体及其用途 | |
| HK1253921B (en) | Multi-ligand drug conjugates and uses thereof |